Hauptmenü öffnen

CK-Wissen β

Bluebrain Theory

Bluebrain Clusterheadache theory. If we ask any Cluster headache (CH) patient to characterize it, his first words will be EXTREME PAIN (kip scale 8-10), around the eye and surrounding area (forehead for the most) of the affected side of the head. My theory is based on an old theory (from the sixties) and on a different version but very much like the theory you can read in clusterbusters called Neurovascular headache and its treatment Hallucinogenic treatment of the ...(I prefer to call it subhallucinogenic). There are two structures involved in this type of headache, the ophthalmic artery branches and the trigeminal nerve specially those branches that run along with the branches of the opht. artery, intracraneal as well as extracraneal. No matter if it is chronic or episodic every CH has two distinctive phases.

1) NEUROLOGICAL, this phase has to do with the abnormal or absence of serotonin release at the presynaptic button, this reaction should happen as an answer to a vasodilatation stimuli (e.g. red wine). Serotonin has a vasoconstriction effect on the extracerebral intracraneal vessels through the 5HT 1B receptors. It seems that this abnormality is local, as if there is a local regulatory system that controls the tone of the artery (based on serotonin), this could explain why this headache is hemi lateral. I know that it has been mentioned that there is a sudden increase of serotonin metabolites in the urine during a CH seizure contrary to my postulate, I could agree that this happens at the very beginning of a CH seizure, all serotonin is released at one time, but there is no refill of the presynaptic vesicles resulting in less or none presence of serotonin and no vasoconstriction. Already there is a question that arises from this statement, why not give an extra dose of serotonin? Sorry but serotonin doesn't cross the brain blood barrier, then what about an extra dose of tryptophan, unfortunately this could end in a serotonin shock. That's why we need a local serotonin substitute that should activate the local 5HT 1B receptors producing a vasoconstriction of the mentioned artery. This phase is painless.

2) VASCULAR, is as mentioned serotonin dependent. This phase depending on how fast it evolves can be divided in two subtypes;

a) If the dilation of the blood vessel occurs more or less slowly (from one to forty minutes in my case), there will be painless symptoms or at the most slight pain (kip scale 4). This phase is called by some SILENT CH, PRODROMES or just PAINLESS phase. Not everybody experiences this phase. Best medicine at this stage is a 5HT 1B AGONIST or a serotonin like compound. Its a kind of warning, a clusterheadache is evolving and if not treated you will experience the extreme pain and symptoms as b).

b) The vasodiltation occurs suddenly and violently, EXTREMELY PAINFUL, almost all of the symptoms that characterize a CH are present. The trigeminal nerve fibers are activated mechanically by the extreme dilated artery running beside the nerve, at the same time and because of this activation there is a release of substance P and calcitonin-gene-related peptide (CGRP) from the nerve. The release of CGRP leads to even more dilation of these blood vessels and an activation of the pain-transmitting neurons.

As far as we know, the use of a 5HT 1D/1F agonist will disrupt these signals. So what kind of medicine are we looking for? No doubt that the ideal will be some that could regulate the release and refill of serotonin "locally" (we mustn't forget that serotonin has different effects in different parts of your body). The second best would be one that was 5HT 1B and 5HT 1D/1F receptor agonist. The majority of the medicine used today are 5HT 1B/1D/1F receptor agonist (e.g. sumatriptan and other triptans and ergotamine) but and this is a big but, they have some serious side-effects due to the presence of almost the same receptors in other organs and blood vessels than in the brain. Another unfortunate effect is that you can't use them (the majority) as preventative , only as abortives, due to its toxicity or due to its short half-life.

I cannot say for certain but if you neutralize the extreme vasodilatation you will stop the pain. Thats why psilocybin/psilocin-based drugs are the most promising for us patients, because they replace the missing serotonin locally by what I call the two stage process, first stage is the affinity of psilocybin to 5HT2A receptors and then, because of MAO psilocybin becomes psilocin which will replace the missing serotonin by reuptake at the presynaptic button. If you compare serotonin with psilocin, you will see a similarity between these compounds (LSD, LSA, sumatriptans are less similar to serotonin )

This was extensive story, but maybe helpful. Best regards Arild Ejsing.

Source CH.com Topic CH theory Apr 24th, 2007

Reference list 5HT1-like and 5HT2A receptors

1. Participation of 5HT1-like and 5HT2A receptors in the contraction of human temporal artery by 5-Hydroxytryptamine and related drugs. Verheggen R. et al, Department of neurosurgery, University of Gottingen, Germany. (VERY IMPORTANT!). Br J Pharmacology, 1996 PMID 8789380

2. 5-Hydroxytryptamine receptors in the human cardiovascular system. Verheggen R, Kaumann AJ, Levy FO., Pharmacology and Therapeutics, 2006, PMID 16960982

3.- Functional 5-HT receptors in human occipital artery. Verheggen R., Archives of Pharmacolgy, 2004 PMID 15007537

4.- 5-HT1B receptors and vascular reactivity in human isolated blood vessels: Assesment of the potential craniovascular selectivity of sumatriptan, Br J of Clinical Pharmacology, 2002

5.- 5HT induced contraction of human temporal arteries coexpressing 5-HT2A receptors and wild-type or variant (Phe124Cys) 5-HT1B receptors: Increased contribution of 5-HT1B receptors to the total contractile amplitude in arteries from Phe124Cys heterozygous individuals. Verheggen R. Pharmacogenetics and genomics, 2006 PMID 16847428

PubMed Search results Author = Verheegen R.

6.- Receptor changes in cerebral arteries after subarachnoid haemorrhage. Hansen-Schwartz, J. Acta Neurologica Scandinavica, 2004

7.- Pharmacological properties of serotonin receptor subtypes mediating contraction of bovine inferior alveolar arteries. O'Donohue H.A. et al., Archives of oral biology, 2004

8.- Contractile 5-HT1B receptors in human cerebral arteries: Pharmacological characterization and localization with immunocytochemistry. Nilsson T. et al, Br J Pharmacology, 1999

9.-Vasoconstriction in human isolated middle meningeal arteries: Determining the contribution the contribution of 5-HT1B and 5-HT1F receptor activation.

10.- Pharmacological analysis of contractile effects of eleptriptan and sumatriptan on human isolated blood vessels. Van Den Broek R.W.M. et al., Br J of clinical Pharmacology, 1999

11.-Can we develop neurally acting drugs for the treatment of migraine. Goadsby P.J., Nature reviews/drug discovery, 2005

12.- Cluster headache: pathogenesis, diagnosis, and management. The Lancet, Arne May, volume 366, 2005

13.- Occipital nerve stimulation for intractable cluster headache. The Lancet, Ambrosini A. volume 369, 2007

14.- Both migraine and motion sickness may be due to low brain levels of serotonin. American Academy of Neurology. American academy of Neurology, 2006

15.-Dropping acid may help headaches. Nature, Arran Frood. News Nature, 2006

16.-Effects of 5-HT1B/1D receptor agonist rizatriptan on cerebral blood flow and blood volume in normal circulation. Hidehiko Okazawa et al., J of Cerebral flow and metabolism, 2006

17.- Serotonin and hallucinogens. Aghajarian G.K. et al. Neuropsychopharmaclology, vol 21, 1999

18.- The drugs inside everyone's brain. Scientific American, Nicoll R.A et al., Scientific American, 2004.

Source: CH.com Topic Reference list (5HT1-like and 5HT2A receptors)

Reference list Ergotamine and others

19.- Indoleamines, the role of serotonin in clinical disorders, Heninger et al, Neuropsychopharmacology, 2000

20.- Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Silberstein, Headache,2003

21.- Research into psilocybin and LSD as cluster headache treatment. MAPS, 2004

22.- 5-HT-moduline: a novel endogenous peptide involved in the control of anxiety. Grimaldi, Neuroscience 1999

23.-Clinical effects of serotonin, General practice notebook. 2005

24.- Response of cluster headache to psilocybin and LSD. Sewell RA, Neurology 2006

25.- Effects of 5-HT 1B/1D receptor agonist rizatriptan on cerebral flow and blood volume in normal circulation. Hidehiko Okazawa, J of cerebral blood flow and metabolism, 2006

26.- Anatomy Atlases www.anatomyatlases.org

27.- Anatomy of the human body, Gray, 1918

28.- Evaluation of the extension of the cerebral blood flow and its main parameters, Gersten,Ben-Gurion University, Israel.

29.- Psychedelic tryptamine carriers. Wikipedia encyclopedia

30.- Cluster headache www.Clusterheadaches.com

31.- Anterior Cingulate and subgenual prefrontal blood flow changes following tryptophan depletion in healthy males. Neuropsychopharmacology, 2006

32.- Autoradiographic distribution os serotonin transporters and receptor subtypes in human brain. Varnaes K. Human brain mapping, 2004.

33. -Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Griffiths RR. Psychopharmacology, 2006

34.- Psychedelics could treat addiction ... www.thetyee.ca, 2006

35.- Risk assesment report relating to paddos(psilocin and psilocybin). The DUTCH GOV. The Hague 2000

36.- Hallucinogenic treatment of neurovascular headaches. www.Clusterbusters.com

37.- Synapses. www.users.rcn.com

38.- Migraines and serotonin receptors. Society for neuroscience, 2005

39.- Respuesta de la cefalea en racimos cronica a la psilocibina. REV NEUROL, 2006 Spanish version

40.- Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Carter OL. University of Queensland, Australia, (Neuropsychopharmacology 2005)

41.- Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 2004

42.- The crucial role of neuronal plasticity in pain and cell death. Corasanti MT. Cell death and differentiation, 2006

43.- Scientists test hallucinogens for mental ills. Blakeslee S, The New York Times.

44.- Cluster headache treatment with Psilocybin mushrooms and LSD. www.erowid.org

45.- DMT and psilocybin research. www.erowid.org

46.- Non-steroidal anti-inflammatory drugs for cancer prevention, Nature reviews, 2006

47.- Cephalalgia, Edited by Goadsby P www.blackwellpublishing.com, 2004

48.- SB-236057-A: a selective 5-HT1B receptor inverse agonist. Roberts C. CNS Drug Rev 2001

49.- The role and therapeutic potential of 5-HT-moduline in psychiatry. Moret C, Semin Clin Neuropsychiatry 2003

50.- Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Scearce-Levie K. Psychopharmacology 1999

51.- The serotonin transporter: a primary target for antidepressant drugs. Schloss P. J Psychopharmacology 1998

52.- Cluster headache. Dr. B. Ekbal, Headache. (book)

53.- Serotonin catabolism www.mrel.beckman.uiuc.edu

54.- The neurotransmitter collection www.microscopy.fsu.edu

55.- Psilocin. Heffter Research institute www.heffter.org

56.- Controlled capillaries. MacVicar B. Nature/neuroscience.

57.- Dropping acid may help headaches. Arran Frood, Nature 2006

58.- Bidirectional control of CNS capillary diameter by pericytes. Pepiatt C. Nature vol 443/12 2006

59.- Human food preferences are associated with a 5HT2A receptor polymorphism. Prado-Lima PS, Molecular psychiatry 2006

60.- A large-scale study on relationship between cerebral blood flow velocity and blood pressure in a natural population. Zhang P. J of Human Hypertension 2006

61.-Effects of tryptophan depletion on the performance of an iterated prisoner's dilemma game in healthy adults. Wood RM. Neuropsychopharmacology, 2006

62.- Can medication overuse headache be treated by abrupt withdrawal of the overused agent. Relja G. Cephalalgia 2006

63.- Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to Verapamil, Langaee TY. Nature vol 81. 2007

64.- Oral rizatriptan-an effective migraine therapy in pediatric patients? Evers S. Nature/clinical practice/neurology 2007

65.- Clusterbusters, Arran Frood, Nature News vol 13 number1, 2007

66.- 5-HT receptors blockade reduces reward attenuation. Benaliouad. Neuropsychopharmacology. 2007

67.- A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T-cells. O'Connel et al. Blood/ American Society of Hematology. 2005

68.- Psychedelics Encyclopedia, P Stafford, (book)

69.- Melatonin, J Russel et al. (book)

70.- Oxford handbook of clinical medicine, RA Hope, (book)

71.- Role of extracellular serotonin levels in the effect of 5-HT1B receptor blockade, De Groote L. Psychopharmacology 2003

72.- SANDOZ and HOFMANN A. Patent database www.espacenet.com

73.- 5-HT1B receptor augmented 5-HT vasoconstrictor response of pulmonary artery in monocrotaline-induced pulmonary hypertensive rats. Wang H-L. Acta Pharmaco. 2001

74.- Methysergide maleate. Sansert. Novartis/Sandoz.

75.- Cluster headache help 2005 www.chhelp.org

76.- Anita's experiment with Kudzu www.chhelp.org

77.- The Serotonin club www.serotoninclub.org

78.- Sex differences in the regulation of serotonergic transmission and behavior in 5-HT receptor knockout mice. Jones M. Neuropsychopharmacology 2005

79.- Ecstasy and serotonin 5-HT1B receptors. EUR J Neuroscience 2003

Source: CH.com Topic Reference list 2,(Ergotamine and others)